NASDAQ: BMEABiomea Fusion Inc Stock
$10.41-0.37 (-3.43%)
Updated Oct 14, 2024
BMEA Price
$10.41
Fair Value Price
$4.88
Market Cap
$376.95M
52 Week Low
$3.61
52 Week High
$22.74
P/E
-2.67x
P/B
3.63x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$139.65M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.31
Operating Cash Flow
-$111M
Beta
0.84
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
BMEA Overview
Biomea Fusion, Inc. is a preclinical-stage biopharmaceutical company focused on the development of irreversible small molecule drugs to treat patients with genetically defined cancers. Its lead candidate, BMF-219, is designed to taken orally to inhibit MENIN, a transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. The company is also using its proprietary FUSION™ System platform to advance a pipeline of covalent treatments against other key oncogenic drivers of cancer. The company was incorporated in 2017 and is headquartered in Redwood City, CA.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BMEA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BMEA ($10.41) is overvalued by 113.16% relative to our estimate of its Fair Value price of $4.88 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
BMEA ($10.41) is not significantly undervalued (113.16%) relative to our estimate of its Fair Value price of $4.88 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
BMEA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more BMEA due diligence checks available for Premium users.
Be the first to know about important BMEA news, forecast changes, insider trades & much more!
BMEA News
Valuation
BMEA fair value
Fair Value of BMEA stock based on Discounted Cash Flow (DCF)
Price
$10.41
Fair Value
$4.88
Overvalued by
113.16%
BMEA ($10.41) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BMEA ($10.41) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BMEA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
BMEA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.67x
Industry
-124.07x
Market
27.44x
BMEA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.63x
Industry
6.12x
BMEA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BMEA's financial health
Profit margin
Revenue
$0.0
Net Income
-$37.3M
Profit Margin
0%
BMEA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$136.2M
Liabilities
$32.2M
Debt to equity
0.31
BMEA's short-term assets ($116.29M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BMEA's short-term assets ($116.29M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BMEA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$32.6M
Investing
-$59.0k
Financing
$1.1M
BMEA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BMEA vs Biotech Stocks
Biomea Fusion Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.